Eli Lilly and Company $LLY Stock Holdings Lifted by Stokes Capital Advisors LLC

Posted by Francis Steltz on Jun 28th, 2026

Eli Lilly and Company logo Stokes Capital Advisors LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 687.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 6,286 shares of the company’s stock after acquiring an additional 5,488 shares during the period. Stokes Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $5,782,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of LLY. Pacific Sage Partners LLC raised its position in shares of Eli Lilly and Company by 15.8% during the first quarter. Pacific Sage Partners LLC now owns 1,524 shares of the company’s stock worth $1,402,000 after purchasing an additional 208 shares during the period. Parker Financial LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $201,000. Xcel Wealth Management LLC increased its stake in Eli Lilly and Company by 3.2% in the 1st quarter. Xcel Wealth Management LLC now owns 388 shares of the company’s stock worth $357,000 after purchasing an additional 12 shares in the last quarter. J2 Capital Management Inc raised its holdings in Eli Lilly and Company by 20.4% during the 1st quarter. J2 Capital Management Inc now owns 839 shares of the company’s stock worth $772,000 after buying an additional 142 shares during the period. Finally, GHP Investment Advisors Inc. raised its holdings in Eli Lilly and Company by 5.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 1,816 shares of the company’s stock worth $1,671,000 after buying an additional 86 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Rothschild & Co Redburn lifted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,235.07.

View Our Latest Research Report on Eli Lilly and Company

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Stock Up 7.0%

LLY stock opened at $1,206.51 on Friday. The company has a 50 day moving average of $1,036.28 and a two-hundred day moving average of $1,020.95. The company has a market cap of $1.14 trillion, a price-to-earnings ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,215.76. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.